ReviewPublished 12 October 2026The liver–gut–bone axis in hepatic osteodystrophy: mechanisms, clinical evidence and therapeutic perspectivesLiangping Zhang · Ting Jiang · Rongqi Cao · Linqiu Han · Ligang NiFrontiers in Cellular and Infection Microbiologydoi 10.3389/fcimb.2026.1935323
ReviewPublished 12 October 2026P2Y 12 inhibition, adenosine signaling, and bone remodeling: differential skeletal pharmacology of antiplatelet agentsZhuoqun Ma · Wei Luo · Yuanbo Li · Hong Li · Chaomin LiFrontiers in Pharmacologydoi 10.3389/fphar.2026.1897702
ReviewPublished 18 September 2026Novel bioactive compounds in the treatment of osteoporosis: chemistry-driven discovery from preclinical validation to clinical translationHonghui Fan · Songtao JinFrontiers in Chemistrydoi 10.3389/fchem.2026.1917991
Musculoskeletal DisordersPublished 23 June 2025Osteoporosis treatment gap and risk of refracture: a pilot retrospective study on a cohort of patients referred to a Fracture Liaison Service in ItalyGiammarco De Mattia · Maria Laura Manca · Vanna Bottai · Damiano Antognetti · Agnese Menconi · Michele Maffi · Marta Mosca · Maurizio MazzantiniFrontiers in Musculoskeletal Disordersdoi 10.3389/fmscd.2025.1620506
